Under the merger plan Folium will become a wholly owned subsidiary of Australis -- which will be rebranded as Folium Biosciences and will carry on the current business of Folium.
Australis Capital to merge with Folium Biosciences in 'transformational deal'
Quick facts: Australis Capital Inc
Price: 0.25 CAD
Market Cap: $41.86 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Australis Capital Inc named herein, including the promotion by the Company of Australis Capital Inc in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE